X-linked hypophosphataemia

Active Ingredient: Burosumab

Indication for Burosumab

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)
Therapeutic intent: Curative procedure

Burosumab is indicated for the treatment of X-linked hypophosphataemia in infants from 1 month to 1 year of age with hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.

For this indication, competent medicine agencies globally authorize below treatments:

0.8 mg/kg once every 2 weeks

For:

Dosage regimens

Subcutaneous, 0.8 milligrams burosumab per kilogram of body weight, once every 2 weeks. The maximum allowed total dose is 2 milligrams burosumab per kilogram of body weight every 2 weeks.

Detailed description

Oral phosphate and active vitamin D analogues (e.g. calcitriol) must be discontinued 1 week prior to initiation of treatment. As burosumab however increases active vitamin D synthesis, patients' requirements for replacement or supplementation with inactive vitamin D should be assessed. Vitamin D replacement or supplementation with inactive forms may be started or continued as per local guidelines under monitoring of serum calcium and phosphate. At initiation, fasting serum phosphate level should be below the reference range for age.

Serum calcium concentration should be monitored before initiation of treatment, and 1-2 weeks after initiation and dose adjustments in addition to regular monitoring during treatment.

The recommended starting dose in children and adolescents aged 1 to 17 years is 0.8 mg/kg of body weight given every 2 weeks. Doses should be rounded to the nearest 10 mg. The maximum dose is 90 mg.

After initiation of treatment with burosumab, fasting serum phosphate should be measured every 2 weeks for the first month of treatment, every 4 weeks for the following 2 months and thereafter as appropriate. Blood samples for measurement of serum phosphate must always be obtained approximately 2 weeks post dose. If fasting serum phosphate is within the reference range for age, the same dose should be maintained.

Dose increase

If fasting serum phosphate is below the reference range for age, the dose may be increased stepwise by 0.4 mg/kg up to a maximum dose of 2.0 mg/kg (maximum dose of 90 mg). Fasting serum phosphate should be measured 4 weeks after dose adjustment. Burosumab should not be adjusted more frequently than every 4 weeks.

Dose decrease

If fasting serum phosphate is above the reference range for age, the next dose should be withheld and the fasting serum phosphate reassessed within 2 weeks. The patient must have fasting serum phosphate below the reference range for age to restart burosumab at half of the previous dose, rounding the amount as described above. If the level remains below the reference range after the first re-initiation dose, the dose can be increased as described under "Dose increase" (above).

Dose conversion at age 18 years

Children and adolescents aged 1 to 17 years should be treated using the dosing guidance outlined above. At 18 years of age the patient should convert to the adult dose and dosing regimen as outlined below.

Missed dose

Treatments may be administered 3 days either side of the scheduled treatment date if needed for practical reasons. If a patient misses a dose, burosumab should be resumed as soon as possible at the prescribed dose.

Dosage considerations

Burosumab should be injected in the arm, abdomen, buttock or thigh.

Injections sites should be rotated and carefully monitored for signs of potential reactions.

1.0 mg/kg once every 4 weeks

For:

Dosage regimens

Subcutaneous, 1 milligrams burosumab per kilogram of body weight, once every 4 weeks.

Detailed description

Oral phosphate and active vitamin D analogues (e.g. calcitriol) should be discontinued 1 week prior to initiation of treatment. Vitamin D replacement or supplementation with inactive forms may be started or continued as per local guidelines under monitoring of serum calcium and phosphate. At initiation, fasting serum phosphate concentration should be below the reference range for age.

The recommended starting dose in adults is 1.0 mg/kg of body weight, rounded to the nearest 10 mg up to a maximum dose of 90 mg, given every 4 weeks.

After initiation of treatment with burosumab, fasting serum phosphate should be measured every 2 weeks for the first month of treatment, every 4 weeks for the following 2 months and thereafter as appropriate. Fasting serum phosphate should be measured 2 weeks after the previous dose of burosumab. If serum phosphate is within the normal range, the same dose should be continued.

Dose decrease

If serum phosphate is above the upper limit of normal range, the next dose should be withheld and the serum phosphate level reassessed within 2 weeks. The patient must have serum phosphate below the normal range before restarting burosumab. Once serum phosphate is below the normal range, treatment may be restarted at half the initial starting dose up to a maximum dose of 40 mg every 4 weeks. Serum phosphate should be reassessed 2 weeks after any change in dose.

Missed dose

Treatments may be administered 3 days either side of the scheduled treatment date if needed for practical reasons. If a patient misses a dose, burosumab should be resumed as soon as possible at the prescribed dose.

Dosage considerations

Burosumab should be injected in the arm, abdomen, buttock or thigh.

Injections sites should be rotated and carefully monitored for signs of potential reactions.

For infants aged 1 month to <6 months 0.4 mg/kg once every 2 weeks and for infants aged 6 months to <1 year of age 0.8 mg/kg once every 2 weeks

For:

Dosage regimens

Regimen A, in the case that patient age in months is ≥ 1 and patient age in months is < 6 :

Subcutaneous, 0.4 milligrams burosumab per kilogram of body weight, once every 2 weeks.

Regimen B, in the case that patient age in months is ≥ 6 and patient age in years is < 1 :

Subcutaneous, 0.8 milligrams burosumab per kilogram of body weight, once every 2 weeks.

Detailed description

Oral phosphate and active vitamin D analogues (e.g. calcitriol) must be discontinued 1 week prior to initiation of treatment. As burosumab however increases active vitamin D synthesis, patients' requirements for replacement or supplementation with inactive vitamin D should be assessed. Vitamin D replacement or supplementation with inactive forms may be started or continued as per local guidelines under monitoring of serum calcium and phosphate. At initiation, fasting serum phosphate level should be below the reference range for age.

Serum calcium concentration should be monitored before initiation of treatment, and 1-2 weeks after initiation and dose adjustments in addition to regular monitoring during treatment.

Dosing in infants with XLH aged 1 month to below 6 months of age

Before initiating treatment, hypophosphataemia should be confirmed by fasting serum phosphate levels below the age-adjusted lower limit of normal (LLN).

The recommended starting dose in infants aged 1 month to below 6 months of age is 0.4 mg/kg of body weight given every 2 weeks. Doses should be rounded to the nearest 1 mg.

After initiation of treatment and after dose adjustment, fasting serum phosphate should be measured every second week for 6 weeks and every 4 weeks for the following 2 months and thereafter as appropriate. Blood samples for measurement of fasting serum phosphate must always be obtained approximately 2 weeks post dose. If fasting serum phosphate is within the reference range for age, the same dose should be maintained.

Dose increase

If fasting serum phosphate is below the reference range for age, the dose may be increased stepwise by 0.2–0.4 mg/kg up to a maximum dose of 0.8 mg/kg. Burosumab should not be increased more frequently than every 4 weeks.

Dose decrease

If fasting serum phosphate is above the reference range for age, the next dose should be withheld and the fasting serum phosphate reassessed within 2 weeks. The patient must have fasting serum phosphate below the reference range for age to restart burosumab at half of the previous dose, rounding the amount as described above. If the level remains below the reference range after the first re-initiation dose, the dose can be increased as described under "Dose increase" (above).

Dose Conversion at 6 months of age

From 6 months of age, if the patient requires a dose increase, the dosing regimen outlined below should be followed.

Dosing in infants with XLH aged 6 months to below 1 year of age

Before initiating treatment, hypophosphataemia should be confirmed by fasting serum phosphate levels below the age-adjusted LLN.

The recommended starting dose in infants aged 6 months to below 1 year is 0.8 mg/kg of body weight given every 2 weeks. Doses should be rounded to the nearest 1 mg.

After initiation of treatment and after dose adjustment, fasting serum phosphate should be measured every second week for 6 weeks and every 4 weeks for the following 2 months and thereafter as appropriate. Blood samples for measurement of fasting serum phosphate must always be obtained approximately 2 weeks post dose. If fasting serum phosphate is within the reference range for age, the same dose should be maintained.

Dose increase

If fasting serum phosphate is below the reference range for age, the dose may be increased stepwise by 0.4 mg/kg up to a maximum dose of 2.0 mg/kg. Burosumab should not be increased more frequently than every 4 weeks.

Dose decrease

If fasting serum phosphate is above the reference range for age, the next dose should be withheld and the fasting serum phosphate reassessed within 2 weeks. The patient must have fasting serum phosphate below the reference range for age to restart burosumab at half of the previous dose, rounding the amount as described above. If the level remains below the reference range after the first re-initiation dose, the dose can be increased as described under "Dose increase" (above).

Dose Conversion at 1 year of age

From 1 year of age, if the patient requires a dose increase, the dosing regimen outlined below should be followed.

Missed dose

Treatments may be administered 3 days either side of the scheduled treatment date if needed for practical reasons. If a patient misses a dose, burosumab should be resumed as soon as possible at the prescribed dose.

Dosage considerations

Burosumab should be injected in the arm, abdomen, buttock or thigh.

Injections sites should be rotated and carefully monitored for signs of potential reactions.

Active ingredient

Burosumab

Burosumab is a recombinant human monoclonal antibody (IgG1) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23). By inhibiting FGF23, burosumab increases tubular reabsorption of phosphate from the kidney and increases serum concentration of 1,25 dihydroxy-Vitamin D.

Read more about Burosumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.

⇈